Wednesday, July 24, 2019 iRECIST training has been a recommended component of immuno-oncology (IO) protocol training documentation in the CCTG Site Training Utility (STU) since 2017. We have recently updated the iRECIST training slides in STU and as of Thursday July 18, 2019, documentation of iRECIST training is now mandatory for Qualified Investigators (QI) participating on new IO trials. In addition to new studies, some recently opened/actively accruing/planned studies will also require documentation of this training for the QI. These trials are: HN9, I227, I238 and I239 (planned). Documentation of completion of iRECIST training for the QI will be required in STU prior to local activation of a site. This is a one-time training requirement for the QI and documentation of previous iRECIST training in STU is acceptable. QIs already active on the trials listed above but have outstanding iRECIST training will receive reminders every 3 months. iRECIST training remains recommended for other roles on an IO trial participants list. Please let the STU team know if you have any questions. stu@ctg.queensu.ca
